Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Cooking tray
Display apparatus, control method thereof, and program
Semiconductor device
Position pointer, variable capacitor and inputting apparatus
Data consumption framework for semantic objects
Apparatus and sensor for adjusting vertical sensor-alignment
  Randomly Featured Patents
Liquid crystalline poly(ester-amides)
Methods and compositions for risk stratification
Method of manufacturing a semiconductor integrated circuit device
Method of making printing plates for offset printing
Display apparatus and assembly of its driving circuit sheet pile connecting element
Injection pump for diesel engines
Bent wire spring clip fasteners
Event notification system and wet well monitor
Crosstalk identification for spectrum management in broadband telecommunications systems